Currently, a phase III study of a dendritic cell vaccine loaded with WT1 peptides (TLP0-001) is being conducted in Japan in patients with advanced pancreatic cancer refractory to standard chemotherapy [71–73]. This evidence concerns the gene WT1 and pancreatic neoplasm.